Use of fasting plasma glucose to determine the approach for diagnosing gestational diabetes mellitus

Diabetes Res Clin Pract. 2023 Nov:205:110952. doi: 10.1016/j.diabres.2023.110952. Epub 2023 Oct 13.

Abstract

Aims: Estimate the impact of OGTTs only on women with a screening FPG of 4.5-5.0 mmol/L using data from HAPO.

Methods: HAPO participants had 75-g OGTTs (24-32 weeks' gestation). At follow-up, children had adiposity assessed (overweight/obesity, obesity) and mothers and children had OGTTs. GDM was defined retrospectively using IADPSG criteria. Odds for neonatal (birthweight, percent neonatal fat, sum of skinfolds, cord C-peptide > 90th percentiles) and follow-up outcomes were assessed in those with HAPO FPG ≤ 4.4 or > 4.4 mmol/L and GDM or no GDM focusing on women with FPG > 4.4 and no GDM (Group 3) vs women with GDM and FPG ≤ 4.4 (Group 2).

Results: This strategy would miss a diagnosis of GDM in 14.7%. Odds for neonatal outcomes in Groups 2 and 3 were not different (ORs: 1.14 to 1.29). Odds at follow-up for type 2 diabetes and disorders of glucose metabolism in mothers were higher in Group 2 (ORs: 3.51, 2.57). Odds for childhood impaired glucose tolerance or adiposity outcomes were not different for Groups 2 and 3.

Conclusions: HAPO mothers whose GDM diagnosis would be missed were not at greater risk for adverse neonatal and childhood outcomes than mothers with FPG of 4.5-5.0 without GDM.

Keywords: Fasting plasma glucose; Gestational diabetes mellitus; Perinatal outcomes.

MeSH terms

  • Blood Glucose / metabolism
  • Child
  • Diabetes Mellitus, Type 2*
  • Diabetes, Gestational* / diagnosis
  • Diabetes, Gestational* / epidemiology
  • Fasting
  • Female
  • Humans
  • Infant, Newborn
  • Obesity
  • Pregnancy
  • Retrospective Studies

Substances

  • Blood Glucose